Skip to main content
Equibles
LONA logo

LONA · LeonaBio, Inc.

Track LONA — free

Use LONA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$7.67 +0.08 (+1.05%) At close · Sep 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based upon the Company’s current operating plan, it estimates that its $51.1 million of cash, cash equivalents and investments at June 30, 2026 may not be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months which raises substantial doubt as to our ability to continue as a going concern following the date of this Quarterly Report on Form 10-Q.”
View the 10-Q filed Aug 14, 2026
Market Cap
$71.51M
Shares
9.42M

LONA metrics

44 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$7.67
Market cap
$71.51M

Price action

19 metrics
Price change (1W)
-5.2%
Price change (30D)
+1.6%
Price change (3M)
-15.9%
Price change (6M)
+36.3%
Price change (YTD)
+0.3%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
108.6%
Beta
0.9
RSI (14D)
45.0
Price vs SMA 50
-5.8%
Price vs SMA 200
+1.8%
Avg volume (3M)
37,077
Relative volume
4.2
Average dollar volume
$308,688

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
9.42M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.1
reciprocal yield 47.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-197.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$122.11M
Net income (TTM)
−$141.46M
Trailing 12 months
Diluted EPS (TTM)
$-23.11
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.98

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+506.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-421.1%
Return on assets
-248.6%
Debt / equity
—
Current ratio
7.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$51.07M
Latest balance sheet
Cash & equivalents
$32.32M
Total assets
$56.89M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$61.93M
Capital expenditures (TTM)
$33,000
R&D (TTM)
$33.50M
SG&A (TTM)
—
Stock compensation (TTM)
$6.71M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
44
13F filer change QoQ
+4
Institutional ownership
77.2%

Short interest

3 metrics
Short interest
0.4%
Latest settlement · 3.5 days to cover
Days to cover
3.5d
Short-squeeze score
42 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1620463 CUSIP 04746L203 13F (30d) 44 filings 43 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)